Veru Inc. (NASDAQ:VERU) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...